The effect of OROS methylphenidate on the sleep of children with attention-deficit/hyperactivity disorder.
We evaluated the effect of OROS methylphenidate (MPH) on sleep quality and architecture in children with attention-deficit/hyperactivity disorder (ADHD) using both a parental sleep questionnaire and polysomnography. Twenty-four ADHD children who had no comorbid psychiatric or sleep disorders except for oppositional defiant disorder completed the 6-week, prospective, open-label, flexible-dose trial with OROS MPH (Concerta) monotherapy. After OROS MPH administration, the polysomnography data indicated that the percentage of stage 2 sleep was increased (P=0.024) and the Number of Awakenings was decreased (P=0.047). Relative to baseline, Parasomnias of the Children's Sleep Habits Questionnaire were decreased (P=0.033). Sleep Onset Latency was not changed during the treatment in general, but was increased in six children with subjective sleep difficulties (F(1)=5.832, P=0.025, eta(2)(p)=0.226). Bedtime Resistance and Sleep Onset Delay in Children's Sleep Habits Questionnaire were also increased during the treatment with OROS MPH only in individuals with sleep complaints (F1=5.001, P=0.036, eta(2)(p)=0.185; F(1)=7.237, P=0.013, eta(2)(p)=0.248). These results suggest that OROS MPH in open-label treatment does not seem to impair sleep and may even improve some aspects of sleep.
Kim
Hyo-Won
HW
Department of Neuropsychiatry, Dongguk University Ilsan Hospital, Korea.
Yoon
In-Young
IY
Cho
Soo-Churl
SC
Kim
Boong-Nyun
BN
Chung
Seockhoon
S
Lee
Hyewon
H
Kim
Chi-Won
CW
Park
Sung-Kun
SK
Yoo
Hee Jeong
HJ
D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications* / Q000188:drug therapy / Q000523:psychology; D002648:Child; D003071:Cognition / Q000502:physiology; D003627:Data Interpretation, Statistical; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D005260:Female; D006801:Humans; D016014:Linear Models; D008297:Male; D008774:Methylphenidate / Q000009:adverse effects* / Q000627:therapeutic use; D017286:Polysomnography; D011569:Psychiatric Status Rating Scales; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D003692:Delayed-Action Preparations; D008774:Methylphenidate